![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Sometimes, you will hear or read unfamiliar medical terms that make it harder to understand multiple myeloma. If your care team is using words you don't understand, it is ok to tell them that you don't understand the words they are using and ask them to explain it in a different way.
| ACT | Adaptive Cell Transfer |
| ADC | Antibody drug conjugate |
| Allo | Allogeneic Stem Cell Transplant |
| ASCO | American Society of Clinical Oncology |
| ASCT | Autologous Stem Cell Transplant |
| ASH | American Society of Hematology |
| Auto | Autologous Stem Cell Transplant |
| BCMA | B-cell maturation antigen |
| BiTE | Bispecific T-cell Engager |
| BMA | Bone Marrow Aspirate or Bone Modifying Agent |
| BMB | Bone Marrow Biopsy |
| BMT | Bone Marrow Transplant |
| BORT | Bortezomib |
| BP | Bisphosphonate |
| CAR | Chimeric antigen receptors |
| CAR-T | A form of immunotherapy that uses specially altered T-cells |
| CBC | Complete Blood Count |
| CBD | Cannbidiol one of 113 cannbinoids in cannabis |
| CD | In cells, refers to Cluster of Differentation |
| CD138 | A protein expressed on plasma cells especially MM cells used as a marker |
| CD34 | A protein marker of hematopoietic stem cells |
| CD38 | A protein marker of cell activation on myeloma cells |
| CR | Complete Response |
| Cr | Creatinine |
| CRAB | CRAB Calcium Renal Anemia Bone Disease |
| CRP C | C-Reactive Protein |
| CRS | Cytokine Release Syndrome |
| CT | Computerized Tomography Scan (3D X-ray) |
| Cy | Cyclophosphamide |
| CyBorD | Cyclophosphamide, Velcade (Bortezomib), Dexamethasone |
| Dara | Daratumumab (Darzalex) |
| DCEP | Dexamethasone, Cyclophosphamide, Etoposide and Cisplatin |
| DEX | Dexamethasone |
| DKd | Daratumumab, carfilzomib, dexamethasone |
| DLC | Digital Life Coaching |
| DLT | Dose-limiting toxicity |
| DPACE | Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide |
| DOR | Duration of Response |
| DRd | Daratumumab, Revlimid, low-dose Dexamethasone |
| DVD | Doxil, Vincristine, Dexamethasone |
| DVT | Deep Vein Thrombosis |
| EFS | Event Free Survival |
| EHR | Electronic health record |
| EMD | Extramedullary Disease (myeloma outside the bone marrow) marrow) |
| EOB | Explanation of benefits |
| ERD | Elotuzumab (Empliciti), Revlimid, Dexamethasone |
| FDA | Federal Drug Administration |
| FISH | Fluorescent In Situ Hybridization |
| FLC | Free Light Chain |
| GEP | Gene Expression Profile |
| GSI | Gamma Secretase Inhibitor |
| GVHD | Graft Versus Host Disease |
| HDAC | Histone Deacetylase |
| HDT | High-Dose Therapy |
| HIPAA | Health Insurance Poratability and Accountability Act |
| HRQoL | Health related Quality of Life |
| HRSMM | High-Risk Smoldering Multiple Myeloma |
| HSC | Hematopoietic stem cells |
| HTU | Healthtree University |
| I | Ixazomib (Ninlaro) |
| IEP | Immunoelectrophoresis |
| IFE | Immunofixation Electrophoresis |
| Ig | Immunoglobulin |
| IM | Intramuscular (shot or injection into the muscle) |
| IMF | International Myeloma Foundation |
| IMiD | Oral immunomodulatory agent |
| IRD | Ixazomib (Ninlaro), Revlimid, Dexamethasone |
| ISS | International Staging System |
| IV | Intravenous (injection into the vein) |
| IVIG | Intravenous Immunoglobulin |
| K | Kyprolis (Carfilzomib) |
| Kd | Carfilzomib, dexamethasone |
| KRD | Kyprolis (Carfilzomib), Revlimid, Dexamethasone |
| Len | Lenadidomide |
| LoD | Limit of Detection (MRD testing) |
| LOT | Lines of Therapy |
| LLS | Leukemia & Lymphoma Society |
| MAB | Monoclonal Antibodies |
| M-protein or spike | Monoclonal protein |
| MDE | Myeloma Defining Event |
| MEL 200 | Dose of melphalan administered in ASCT: 200 mg of melphalan per square meter of body mass |
| MGUS | Monoclonal Gammopathy of Undetermined Significance |
| MMRF | Multiple Myeloma Research Foundation |
| MP | Melphalan & Prednisone |
| MPR | Melphalan, Prednisone, Revlimid |
| MPT | Melphalan, Prednisone, Thalidomide |
| MR | Minimal Response (between 25% and 50% response) |
| MRD | Minimal Residual Disease |
| MRD Neg | Absence of tumor plasma cell within 1,000,000 bone marrow cells |
| MRI | Magnetic Resonance Imaging |
| MTD | Maximum Tolerated Dose |
| NA or N/A | Not Available |
| nCR | Near-Complete Response |
| NDMM | Newly Diagnosed Multiple Myeloma |
| NGF | Next-Generation Flow (new 8-color flow cytometry test) |
| NGS | Next-Generation Sequencing (new DNA-sequencing test) |
| NK | Natural Killer (cell) |
| NR | Not Reached |
| ONJ | Osteonecrosis of the Jaw |
| ORR | Overall Response Rate |
| OS | Overall survival |
| PBSCT | Peripheral Blood Stem Cell Transplant |
| PCLI | Plasma Cell Labeling Index |
| PDC | Peptide-drug conjugate |
| PET | Positron Emission Tomography |
| PET/CT | PET combined with a CT scan |
| PFS | Progression-Free Survival |
| PI | Protenase Inhibitor |
| PN | Peripheral Neuropathy |
| POM | Pomalidomide (Pomalyst®) |
| PR | Partial Response |
| PSCT | Peripheral Stem Cell Transplant |
| QoL | Quality of Life |
| RBC | Red Blood Cells |
| REVLoDEX | Revlimid, low-dose Dexamethasone |
| RMPT | Revlimid, Melphalan, Prednisone, Thalidomide |
| RRMM | Relapsed/Refractory Multiple Myeloma |
| RVd | Revlimid, Velcade, low-dose Dexamethasone |
| RVD | Revlimid, Velcade, Dexamethasone |
| RWD | Real world data |
| sCR | Stringent Complete Response (CR plus normal free light chain ratio and no clonal plasma cells) |
| SCT | Stem Cell Transplant |
| SD | Stable Disease |
| SINE | Selective Inhibitor of Nuclear Export (Selinexor) |
| SMM | Smoldering Multiple Myeloma |
| SPEP | Serum Protein Electrophoresis |
| SPM | Second Primary Malignancy |
| SQ | Subcutaneous (sometimes abbreviated SC) |
| SRE | Skeletal Related Event |
| ß2M | Beta-2 Microglobulin |
| TCR | T-cell Receptor |
| TMI | Too Much Information |
| TTP | Time to Progression |
| UHiR | Ultra-High Risk |
| UPEP | Urine Protein Electrophoresis |
| VCF | Vertebral Compression Fracture |
| VDT-PACE | Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide |
| VEGF | Vascular Endothelial Growth Factor |
| VGPR | Very Good Partial Response |
| VMP-Dara | Velcade, Melphalan, Prednisone plus Daratumumab (RRMM) |
| VRd | Velcade, Revlimid, Low-Dose Dexamethasone |
| VTD | Velcade, Thalidomide, Dexamethasone |
| VTD-Dara | Velcade, Thalidomide, Dexamethasone, Daratumumab |
| WBC | White Blood Cells |
| WBLD CT | Whole-Body Low-Dose CT |
| WBLD MRI | Whole-Body Low-Dose MRI |
| ZOL |
Zoledronic acid (Zometa) |
Sometimes, you will hear or read unfamiliar medical terms that make it harder to understand multiple myeloma. If your care team is using words you don't understand, it is ok to tell them that you don't understand the words they are using and ask them to explain it in a different way.
| ACT | Adaptive Cell Transfer |
| ADC | Antibody drug conjugate |
| Allo | Allogeneic Stem Cell Transplant |
| ASCO | American Society of Clinical Oncology |
| ASCT | Autologous Stem Cell Transplant |
| ASH | American Society of Hematology |
| Auto | Autologous Stem Cell Transplant |
| BCMA | B-cell maturation antigen |
| BiTE | Bispecific T-cell Engager |
| BMA | Bone Marrow Aspirate or Bone Modifying Agent |
| BMB | Bone Marrow Biopsy |
| BMT | Bone Marrow Transplant |
| BORT | Bortezomib |
| BP | Bisphosphonate |
| CAR | Chimeric antigen receptors |
| CAR-T | A form of immunotherapy that uses specially altered T-cells |
| CBC | Complete Blood Count |
| CBD | Cannbidiol one of 113 cannbinoids in cannabis |
| CD | In cells, refers to Cluster of Differentation |
| CD138 | A protein expressed on plasma cells especially MM cells used as a marker |
| CD34 | A protein marker of hematopoietic stem cells |
| CD38 | A protein marker of cell activation on myeloma cells |
| CR | Complete Response |
| Cr | Creatinine |
| CRAB | CRAB Calcium Renal Anemia Bone Disease |
| CRP C | C-Reactive Protein |
| CRS | Cytokine Release Syndrome |
| CT | Computerized Tomography Scan (3D X-ray) |
| Cy | Cyclophosphamide |
| CyBorD | Cyclophosphamide, Velcade (Bortezomib), Dexamethasone |
| Dara | Daratumumab (Darzalex) |
| DCEP | Dexamethasone, Cyclophosphamide, Etoposide and Cisplatin |
| DEX | Dexamethasone |
| DKd | Daratumumab, carfilzomib, dexamethasone |
| DLC | Digital Life Coaching |
| DLT | Dose-limiting toxicity |
| DPACE | Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide |
| DOR | Duration of Response |
| DRd | Daratumumab, Revlimid, low-dose Dexamethasone |
| DVD | Doxil, Vincristine, Dexamethasone |
| DVT | Deep Vein Thrombosis |
| EFS | Event Free Survival |
| EHR | Electronic health record |
| EMD | Extramedullary Disease (myeloma outside the bone marrow) marrow) |
| EOB | Explanation of benefits |
| ERD | Elotuzumab (Empliciti), Revlimid, Dexamethasone |
| FDA | Federal Drug Administration |
| FISH | Fluorescent In Situ Hybridization |
| FLC | Free Light Chain |
| GEP | Gene Expression Profile |
| GSI | Gamma Secretase Inhibitor |
| GVHD | Graft Versus Host Disease |
| HDAC | Histone Deacetylase |
| HDT | High-Dose Therapy |
| HIPAA | Health Insurance Poratability and Accountability Act |
| HRQoL | Health related Quality of Life |
| HRSMM | High-Risk Smoldering Multiple Myeloma |
| HSC | Hematopoietic stem cells |
| HTU | Healthtree University |
| I | Ixazomib (Ninlaro) |
| IEP | Immunoelectrophoresis |
| IFE | Immunofixation Electrophoresis |
| Ig | Immunoglobulin |
| IM | Intramuscular (shot or injection into the muscle) |
| IMF | International Myeloma Foundation |
| IMiD | Oral immunomodulatory agent |
| IRD | Ixazomib (Ninlaro), Revlimid, Dexamethasone |
| ISS | International Staging System |
| IV | Intravenous (injection into the vein) |
| IVIG | Intravenous Immunoglobulin |
| K | Kyprolis (Carfilzomib) |
| Kd | Carfilzomib, dexamethasone |
| KRD | Kyprolis (Carfilzomib), Revlimid, Dexamethasone |
| Len | Lenadidomide |
| LoD | Limit of Detection (MRD testing) |
| LOT | Lines of Therapy |
| LLS | Leukemia & Lymphoma Society |
| MAB | Monoclonal Antibodies |
| M-protein or spike | Monoclonal protein |
| MDE | Myeloma Defining Event |
| MEL 200 | Dose of melphalan administered in ASCT: 200 mg of melphalan per square meter of body mass |
| MGUS | Monoclonal Gammopathy of Undetermined Significance |
| MMRF | Multiple Myeloma Research Foundation |
| MP | Melphalan & Prednisone |
| MPR | Melphalan, Prednisone, Revlimid |
| MPT | Melphalan, Prednisone, Thalidomide |
| MR | Minimal Response (between 25% and 50% response) |
| MRD | Minimal Residual Disease |
| MRD Neg | Absence of tumor plasma cell within 1,000,000 bone marrow cells |
| MRI | Magnetic Resonance Imaging |
| MTD | Maximum Tolerated Dose |
| NA or N/A | Not Available |
| nCR | Near-Complete Response |
| NDMM | Newly Diagnosed Multiple Myeloma |
| NGF | Next-Generation Flow (new 8-color flow cytometry test) |
| NGS | Next-Generation Sequencing (new DNA-sequencing test) |
| NK | Natural Killer (cell) |
| NR | Not Reached |
| ONJ | Osteonecrosis of the Jaw |
| ORR | Overall Response Rate |
| OS | Overall survival |
| PBSCT | Peripheral Blood Stem Cell Transplant |
| PCLI | Plasma Cell Labeling Index |
| PDC | Peptide-drug conjugate |
| PET | Positron Emission Tomography |
| PET/CT | PET combined with a CT scan |
| PFS | Progression-Free Survival |
| PI | Protenase Inhibitor |
| PN | Peripheral Neuropathy |
| POM | Pomalidomide (Pomalyst®) |
| PR | Partial Response |
| PSCT | Peripheral Stem Cell Transplant |
| QoL | Quality of Life |
| RBC | Red Blood Cells |
| REVLoDEX | Revlimid, low-dose Dexamethasone |
| RMPT | Revlimid, Melphalan, Prednisone, Thalidomide |
| RRMM | Relapsed/Refractory Multiple Myeloma |
| RVd | Revlimid, Velcade, low-dose Dexamethasone |
| RVD | Revlimid, Velcade, Dexamethasone |
| RWD | Real world data |
| sCR | Stringent Complete Response (CR plus normal free light chain ratio and no clonal plasma cells) |
| SCT | Stem Cell Transplant |
| SD | Stable Disease |
| SINE | Selective Inhibitor of Nuclear Export (Selinexor) |
| SMM | Smoldering Multiple Myeloma |
| SPEP | Serum Protein Electrophoresis |
| SPM | Second Primary Malignancy |
| SQ | Subcutaneous (sometimes abbreviated SC) |
| SRE | Skeletal Related Event |
| ß2M | Beta-2 Microglobulin |
| TCR | T-cell Receptor |
| TMI | Too Much Information |
| TTP | Time to Progression |
| UHiR | Ultra-High Risk |
| UPEP | Urine Protein Electrophoresis |
| VCF | Vertebral Compression Fracture |
| VDT-PACE | Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide |
| VEGF | Vascular Endothelial Growth Factor |
| VGPR | Very Good Partial Response |
| VMP-Dara | Velcade, Melphalan, Prednisone plus Daratumumab (RRMM) |
| VRd | Velcade, Revlimid, Low-Dose Dexamethasone |
| VTD | Velcade, Thalidomide, Dexamethasone |
| VTD-Dara | Velcade, Thalidomide, Dexamethasone, Daratumumab |
| WBC | White Blood Cells |
| WBLD CT | Whole-Body Low-Dose CT |
| WBLD MRI | Whole-Body Low-Dose MRI |
| ZOL |
Zoledronic acid (Zometa) |
Thanks to our HealthTree Community for Chronic Lymphocytic Leukemia Sponsors:
Follow Us
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2024 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811